Osimertinib—first or second line for epidermal growth factor (EGFR) mutation-positive non-small cell lung cancer?

Epidermal growth factor (EGFR) M+ non-small cell lung cancer (NSCLC) accounts for about 10% of non-squamous NSCLC in Europe and North America and as much as 40% in women in Asian countries (1).